Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Pricing On The Right Side Of The Inflation Debate – At The Wrong Time

Executive Summary

The US pharmaceutical industry is finally on the right side of the inflation debate, with drug price increases clearly lagging well behind overall consumer price growth. It is, however, probably too late to make a difference in the prospects of price control legislation.

You may also be interested in...

Rx Pricing: Insulin Costs Would Go Up Under Senate Bill; Biden Pushes Summer Action On Broader Plan

CBO highlights the pharma-friendly nature of Senate’s plan to limit patient cost-sharing for insulin. Meanwhile, White House urges Senate to pass Democrat’s more comprehensive and pharma-negative drug pricing bill instead of waiting for the revival of the Build Back Better deal.

Senate Drug Pricing Bill: Even Worse Than The House Version

US Senate’s updated version of drug pricing legislation is even worse for industry when it comes to the proposed price ‘negotiation’ authority, a Congressional Budget Office analysis indicates. The big numbers facing the industry just keep getting bigger.

Senate Insulin Bill Focuses On List Prices With Carrot For Manufacturers, Stick For PBMs

US legislation attempts to address manufacturer, pharmacy benefit manager impact on patient costs in addition to health plan benefit designs. Critics suggest it’s too easy on manufacturers but that may help its chances with Republicans.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts